2.01

9.24% 0.17

After Hours: 2.01

Mersana Therapeutics Inc (MRSN)

Overview News Price History Option Chain Financials Discussions Forecast

Mersana Therapeutics Inc stock is traded at $2.01, with a volume of 764.61K. It is up +9.24% in the last 24 hours and down -5.19% over the past month. Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Previous Close:

$1.84

Open:

$1.81

24h Volume:

764.61K

Relative Volume:

0.83

Market Cap:

$242.90M

Revenue:

$36.86M

Net Income/Loss:

$-171.67M

P/E Ratio:

-0.9853

EPS:

-2.04

Net Cash Flow:

$-171.05M

1W Performance:

+3.61%

1M Performance:

-5.19%

6M Performance:

-41.91%

1Y Performance:

+41.55%

1-Day Range:

$1.80

$2.04

1-Week Range:

$1.80

$2.04

52-Week Range:

$1.15

$6.2801

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name

Mersana Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

617-498-0020

Address

840 MEMORIAL DRIVE, CAMBRIDGE

Employee

123

Twitter

@MersanaADC

Next Earnings Date

2024-11-05

Latest SEC Filings

MRSN's Discussions on Twitter

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-04-23	Upgrade	Citigroup	Neutral → Buy
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-27-23	Downgrade	BTIG Research	Buy → Neutral
Jul-27-23	Downgrade	Citigroup	Buy → Neutral
Jul-27-23	Downgrade	Guggenheim	Buy → Neutral
Jul-27-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-27-23	Downgrade	Truist	Buy → Hold
Jul-27-23	Downgrade	Wedbush	Outperform → Neutral
Jun-16-23	Downgrade	JP Morgan	Overweight → Neutral
Jun-15-23	Initiated	Guggenheim	Buy
Mar-16-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-20-23	Initiated	Citigroup	Buy
Nov-21-22	Initiated	Truist	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Aug-30-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	Credit Suisse	Neutral
Dec-03-20	Initiated	Stifel	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Apr-29-20	Initiated	BTIG Research	Buy
Jan-21-20	Reiterated	H.C. Wainwright	Buy
Mar-11-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-18	Upgrade	Leerink Partners	Mkt Perform → Outperform
May-08-18	Initiated	Robert W. Baird	Outperform
Mar-19-18	Downgrade	JP Morgan	Overweight → Neutral

View All

Mersana Therapeutics Inc Stock (MRSN) Latest News

Nov 02, 2024

MRSN (Mersana Therapeutics) Revenue : $29.94 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 02, 2024

Oct 30, 2024

Mersana Therapeutics exec Bala Mohan sells stock worth $3,579 - Investing.com India

Oct 30, 2024

Oct 29, 2024

Mersana Therapeutics exec Bala Mohan sells stock worth $3,579 By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 25, 2024

SG Americas Securities LLC Reduces Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Oct 25, 2024

Oct 23, 2024

Mersana Therapeutics Inc’s Market Journey: Closing Weak at 2.05, Down -2.38 - The Dwinnex

Oct 23, 2024

Oct 22, 2024

Exchange Traded Concepts LLC Acquires 41,586 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Oct 22, 2024

Oct 17, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Average Price Target from Brokerages - Defense World

Oct 17, 2024

Oct 15, 2024

SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc - GuruFocus.com

Oct 15, 2024

Investing in Mersana Therapeutics Inc (MRSN) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News

Oct 15, 2024